Form 4: Director William Waddill Executes PTGX Stock Sale

Protagonist Therapeutics director William D. Waddill exercised stock options and sold 9,000 shares under a 10b5-1 trading plan.

Summary

• Director William D. Waddill exercised options to acquire 9,000 shares of Protagonist Therapeutics common stock.
• The acquisitions consisted of 3,000 shares at $11.80 and 6,000 shares at $16.54.
• Following the acquisition, the director sold 9,000 shares at a weighted average price of $107.68.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-established 10b5-1 plan, which is a routine mechanism for insider liquidity.

Positives

• The director maintains a remaining beneficial ownership of 7,825 shares of common stock.
• The transactions were conducted under a pre-arranged 10b5-1 plan, indicating systematic rather than reactive selling.

Negatives

• The director reduced their direct holdings in the company through the sale of 9,000 shares.

Risks

• Future share price volatility could impact the value of remaining holdings.
• Reliance on 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for liquidity and diversification among biotech executives and directors, and is generally viewed as neutral by the market when pre-planned.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard corporate governance practice in the biotechnology sector to avoid allegations of insider trading.
• The sale price of $107.68 reflects significant appreciation from the original option exercise prices of $11.80 and $16.54.

Stakeholder Impact

• Shareholders should note the reduction in direct insider ownership, though the volume is limited relative to total outstanding shares.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Protagonist Therapeutics, PTGX, Insider Trading, Form 4, Stock Options, 10b5-1